Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Endometrial cancer with no specific molecular profile, drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Splitting the class into truly low-risk and higher-risk tumours with L1CAM, CTNNB1 and receptor status.
Whether progestins can replace chemotherapy after surgery.
Small immunotherapy benefit in proficient tumours.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 14 changes by month →When this page itself was last checked or edited.
Primary PFS endpoint not met; mPFS 12.
A milestone in how this cancer is treated.
PFS HR 0.
OS 44.
A milestone in how this cancer is treated.